Overview and Scope
Intranasal drug delivery devices are medical devices that deliver medications into the nasal cavity. These devices are intended to administer medications directly to the nasal mucosa, which is highly vascularized and has a huge surface area, allowing the drug to be absorbed into the bloodstream quickly. It delivers drugs or therapeutic substances in various forms, including sprays, powders, or liquid solutions, directly into the nasal cavity.
Sizing and Forecast
The intranasal drug delivery devices market size has grown strongly in recent years. It will grow from $55.27 billion in 2023 to $60.27 billion in 2024 at a compound annual growth rate (CAGR) of 9.0%. The growth in the historic period can be attributed to rise in chronic respiratory diseases, patient preference and compliance, convenience in self-administration, pediatric applications, market expansion in allergic rhinitis treatment, wider range of indications..
The intranasal drug delivery devices market size is expected to see strong growth in the next few years. It will grow to $84.51 billion in 2028 at a compound annual growth rate (CAGR) of 8.8%. The growth in the forecast period can be attributed to increasing geriatric population, rising global respiratory issues, expanding applications in neurological disorders, personalized medicine trends, preventive healthcare initiatives, market penetration in emerging economies.. Major trends in the forecast period include advances in formulation technologies, focus on pediatric and geriatric applications, rise in self-administration devices, nasal powder inhalers, incorporation of biologics and peptides..
Order your report now for swift delivery, visit the link:
https://www.thebusinessresearchcompany.com/report/intranasal-drug-delivery-devices-global-market-report
Segmentation & Regional Insights
The intranasal drug delivery devices market covered in this report is segmented –
1) By Product: Powder Delivery Device, Liquid Delivery Device, Pressurized Metered-Dose Inhalers, Other Products
2) By Dosage: Unit-Dose, Multi-Dose
3) By Application: Chronic Obstructive Pulmonary Disease (COPD), Rhinitis, Cystic Fibrosis, Nasal Congestion, Asthma, Other Applications
4) By End User: Hospitals, Clinics, Homecare, Other End Users
North America was the largest region in the intranasal drug delivery devices market in 2023. The regions covered in the intranasal drug delivery devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Intrigued to explore the contents? Secure your hands-on a free sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13463&type=smp
Major Driver Impacting Market Growth
The increasing prevalence of chronic diseases is expected to propel the growth of the intranasal drug delivery devices market going forward. Chronic diseases can be defined as conditions that last 1 year or more and require ongoing medical attention, limit activities of daily living, or both. Intranasal drug delivery devices are used to manage chronic diseases by providing a non-invasive and efficient way to administer medications. They allow medications to be delivered directly to the affected area, which is convenient, making it easy to use and promoting rapid absorption. For instance, in September 2022, according to a report published by the National Institutes of Health (NIH), a US-based biomedical research agency, in 2023, in the United States, the number of people aged 50 and older with at least one chronic illness is predicted to rise by 99.5%, from 71.522 million in 2020 to 142.66 million in 2050. Additionally, the number of people with multimorbidity would rise by 91.16% from 7.8304 million in 2020 to 14.968 million in 2050. Therefore, the increasing prevalence of chronic diseases is driving the growth of the intranasal drug delivery devices market.
Key Industry Players
Major companies operating in the intranasal drug delivery devices market report are Johnson and Johnson Inc., Merck and Co.Inc., Novartis AG, AstraZeneca plc., GlaxoSmithKline Plc, 3M Company, Becton, Dickinson and Company, Teva Pharmaceutical Industries Ltd., AptarGroup Inc., West Pharmaceutical Services Inc., Teleflex Incorporated, Recipharm AB, Nemera Development S.A., Consort Medical plc., Vectura Group plc, Douglas Pharmaceuticals Ltd., Avanir Pharmaceuticals, OptiNoset Inc., Flamel Technologies , Aegis Therapeutics LLC, Sonoma Pharmaceuticals, PendoPharm Inc., Kurve Technology Inc., Impel NeuroPharma, Impexium Medical Products, B.F. Ascher and Company Inc., ENT Technologies Pty. Ltd., Neurelis Inc., Generex Biotechnology Corporation</b
The intranasal drug delivery devices market report table of contents includes:
1. Executive Summary
2. Intranasal Drug Delivery Devices Market Characteristics
3. Intranasal Drug Delivery Devices Market Trends And Strategies
4. Intranasal Drug Delivery Devices Market – Macro Economic Scenario
5. Global Intranasal Drug Delivery Devices Market Size and Growth
.
.
.
32. Global Intranasal Drug Delivery Devices Market Competitive Benchmarking
33. Global Intranasal Drug Delivery Devices Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Intranasal Drug Delivery Devices Market
35. Intranasal Drug Delivery Devices Market Future Outlook and Potential Analysis
36. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
